Impact of Clomiphene Citrate Administration During the Early Luteal Phase on Endocrine Profile in IVF Cycles
Information source: Fundació Privada Eugin
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Female Infertility
Intervention: Clomifene Citrate (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Fundació Privada Eugin Official(s) and/or principal investigator(s): Marta Colodron, MD, Principal Investigator, Affiliation: Clinica EUGIN
Summary
The purpose of this study is to evaluate the effect on LH levels of the 5-day CC
administration during luteal phase in oocyte donors, to investigate whether the CC corrects
the suppressed LH levels in the luteal phase and whether it prolongs the luteal phase in the
agonist triggered antagonist cycles.
Clinical Details
Official title: Impact of Clomiphene Citrate Administration During the Early Luteal Phase on Endocrine Profile in Agonist Triggered GnRH Antagonist in Vitro Fertilization Cycles. Phase IV, Single-centre, Open-label, Controlled Clinical Trial.
Study design: Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label
Primary outcome: LH Levels (IU)
Secondary outcome: Endometrial development (Noyes criteria)
Eligibility
Minimum age: 18 Years.
Maximum age: 35 Years.
Gender(s): Female.
Criteria:
Inclusion Criteria:
- Oocyte donors
- 18-35 years old
- BMI 18-29 Kg/m2
- Normal basal hormonal levels
- No contraceptive pill
Exclusion Criteria:
- Polycystic ovarian syndrome (PCOS)
- Previous participation in the study
Locations and Contacts
ClÃnica EUGIN, Barcelona 08029, Spain
Additional Information
Starting date: June 2012
Last updated: February 12, 2013
|